Popular terms

Elan topics
Folic Acid
Carbon Dioxide
Antibodies
Immune Response
High Energy
Inorganic Compounds
Electrolysis
Semiconductor Material
Semiconductor
Hydrogen Production From Water
Female Sexual Dysfunction
Dysfunction
Sexual Dysfunction
Mammography
Radiograph

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Elan patents



      

This page is updated frequently with new Elan-related patent applications.




Date/App# patent app List of recent Elan-related patents
05/19/16
20160143195 
 Immobilized melanin and its chemical derivatives for the harvesting or shielding of high energy electromagnetic radiation patent thumbnailImmobilized melanin and its chemical derivatives for the harvesting or shielding of high energy electromagnetic radiation
A method and apparatus for a photocatalytic and electrolytic electromagnetic shielding and responsive polymer includes in various aspects one or more electromagnetic shielding and responsive polymers, a method for forming a electromagnetic shielding and responsive polymer, an electrolytic electromagnetic energy dispersion cell, and a reaction method, as well as applications.. .

05/19/16
20160139132 
 Method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm patent thumbnailMethod of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression of cavcolin-1, cavcolin-2, vimentin, calponon2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, ef-i-delta, or m2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.. .
Thomas Jefferson University


05/19/16
20160136132 
 A pharmaceutical combination for the treatment of melanoma patent thumbnailA pharmaceutical combination for the treatment of melanoma
The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (cdk) inhibitor represented by a compound of formula i (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a braf inhibitor or a mek inhibitor, for use in the treatment of melanoma. The present invention also relates to a method for the treatment of melanoma comprising administering to a subject in need thereof, a therapeutically effective amount of a cdk inhibitor and a therapeutically effective amount of at least one anticancer agent selected from a braf inhibitor or a mek inhibitor..
Piramal Enterprises Limited


05/19/16
20160136079 
 A3 adenosine receptor ligands for modulation of pigmentation patent thumbnailA3 adenosine receptor ligands for modulation of pigmentation
The present invention relates to compositions and methods for modulating melanin production, secretion and/or accumulation in human skin cells. In particular, the present invention relates to the use of a3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of a3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin..
Oradin Pharmaceutical Ltd.


05/19/16
20160136070 
 Methods and compositions for enhancing skin pigmentation patent thumbnailMethods and compositions for enhancing skin pigmentation
Described herein are methods and compositions useful for enhancing pigmentation, such as skin, eye and/or hair pigmentation comprising administering e.g., an nnt inhibitor or an agent that modifies redox status in a melanocyte.. .
The General Hospital Corporation


05/19/16
20160135889 
 Method for depilation by photothermolysis with melanin patent thumbnailMethod for depilation by photothermolysis with melanin
Improved melanin-enhanced photothermolysis hair removal method, which includes the application of liposome-encapsulated melanin solutions as a chromophore onto the skin and the use of mechanical devices having microneedles to favor absorption thereof by the hair follicles.. .
Dermopartners,s.l.


05/12/16
20160130625 
 Methods for producing melanin and inorganic fertilizer from fermentation leachates patent thumbnailMethods for producing melanin and inorganic fertilizer from fermentation leachates
Melanin or inorganic fertilizers are produced from fermentation leachates or from low-cost nutrient-rich solutions. The method for producing the melanin or inorganic fertilizer comprises repetitive trophic cycling in the controlled conditions of primary and secondary bioreactors.
River Road Research, Inc.


05/12/16
20160130534 
 Pourable detergent composition comprising suspended particles patent thumbnailPourable detergent composition comprising suspended particles
The present invention relates to a pourable thixotropic detergent composition comprising a continuous phase and at least 0.3 wt. % of suspended particles comprising water-soluble surfactant, said continuous phase containing at least 10 wt.
Conopco, Inc., D/b/a Unilever


05/12/16
20160130532 
 Hygroscopic detergent formulation comprising water, aminocarboxylate chelant and moisture-sensitive ingredients patent thumbnailHygroscopic detergent formulation comprising water, aminocarboxylate chelant and moisture-sensitive ingredients
The present invention relates to a detergent formulation comprising water, one or more moisture-sensitive detergent ingredients and an aminocarboxylate chelant comprising at least three carboxylate residues; wherein the combination of aminocarboxylate chelant and water represents at least 20% by weight of the detergent formulation; wherein the weight ratio of aminocarboxylate chelant to water lies within the range of 5:6 to 5:1; and wherein the detergent formulation has a ph in the range of 7.2 to 12. The detergent composition offers the advantage that adverse effects of water uptake during storage are minimized.
Conopco, Inc., D/b/a Unilever


05/12/16
20160129077 
 Use of recombinant ganoderma immunoregulatory protein (rlz-8) in preparation of drug for treating melanoma patent thumbnailUse of recombinant ganoderma immunoregulatory protein (rlz-8) in preparation of drug for treating melanoma
A use of recombinant ganoderma immunoregulatory protein (rlz-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rlz-8 is researched, which indicates that the rlz-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma..

05/12/16
20160129009 

High purity diaminophenothiazinium compounds including methylthioninium chloride (mtc)


This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including methythioninium chloride (mtc) (also known as methylene blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (nos); nitrosyl reduction (nr); thiosulfonic acid formation (tsaf); oxidative coupling (oc); cr(vi) reduction (cr); isolation and purification of zwitterionic intermediate (iapozi); ring closure (rc); chloride salt-formation (csf); one of: sulphide treatment (st); dimethyldithiocarbamate treatment (dt); carbonate treatment (ct); ethylenediaminetetraacetic acid treatment (edtat); organic extraction (oe); and recrystallisation (rx).
Wista Laboratories Ltd.


05/05/16
20160122323 

Inhibitors of cyclin-dependent kinase 7 (cdk7)


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


05/05/16
20160122314 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals, Inc.


05/05/16
20160120914 

Treating a lymphoma with a whole, leech saliva extract


Methods are also provided for isolating and using a whole-saliva leech extract in the treatment of a melanoma. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° c.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech.
Biopep Solutions, Inc.


04/28/16
20160115555 

Biomarkers for differentiating melanoma from benign nevus in the skin


Disclosed is a method for diagnosing melanoma in a human subject, as well as a method for providing a prognosis to a human subject who is at risk of developing melanoma recurrence, and a method for determining the stage of melanoma in a human subject, comprising the step of determining the level of expression of phosphatase and actin regulator 1 (phactr1) gene, or fragments thereof, either alone or in combination with the level of expression of secreted integrin-binding phosphoprotein (spp1), preferentially expressed antigen in melanoma (prame), growth differentiation factor 15 (gdf15), and chemokine c-x-c motif ligand 10 (cxcl10) genes. Further, the invention relates to a diagnostic kit, comprising at least one substance for detection of the expression of phactr1, or fragments thereof, either alone or in combination with the detection of spp1, prame, gdf15, and cxcl10, for the diagnosis or prognosis of melanoma..
Advanced Cell Diagnostics


04/28/16
20160115468 

Albumin-binding arginine deiminase for cancer targeting treatment and detection of arginine


The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase (aad) fusion protein for treating cancer or other arginine-dependent diseases. The aad fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (hsa) or animal serum albumin and has its high activity with longer half life for efficient depletion of arginine in cancer cells.
Vision Global Holdings Ltd.


04/28/16
20160115131 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals. Inc.


04/28/16
20160113935 

Composition including atm inhibitor for reducing cellular senescence and use of the composition


A composition including an ataxia telangiectasia mutated (atm) inhibitor for reducing cellular senescence, a method of reducing cellular senescence in a mammal, and a method of treating a symptom associated with cellular senescence in a mammal.. .
Samsung Electronics Co., Ltd.


04/28/16
20160113914 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals, Inc.


04/21/16
20160108046 

Inhibitors of lysine specific demethylase-1


The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds.

04/21/16
20160108033 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic diseases. Provided herein are substituted imidazole-pyridine derivative compounds and pharmaceutical compositions comprising said compounds.

04/21/16
20160108032 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrrolopyridine derivative compounds and pharmaceutical compositions comprising said compounds.

04/21/16
20160107995 

Histone demethylase inhibitors


The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds.

04/21/16
20160106853 

Curcumin conjugates for treating and preventing cancers


Conjugating lhrh to curcumin (lhrh-curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing lhrh receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used against cancer cells that express the lhrh receptor: pancreas, prostate, breast, testicular, uterine, ovarian, melanoma.

04/14/16
20160102242 

Treatment fluid and method


A treatment fluid made of mineral acid, viscoelastic surfactant, at least one of a fluoride source and a chelant, and optionally a corrosion inhibitor. A method of combining a mineral acid, viscoelastic surfactant, at least one of a fluoride source and a chelant, and optionally a corrosion inhibitor, in a fluid mixture.

04/07/16
20160096841 

Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith


Wherein r1, r2, and r3 are as defined herein, compositions comprising an effective amount of an aminopurine compound, and methods for treating or preventing a cancer, for example, melanoma.. .

04/07/16
20160096825 

Furanone compounds as kinase inhibitors


The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as raf kinase, especially braf kinase, inhibitors, which are useful therapeutic agents for treatment of raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds..
Eternity Bioscience Inc.


04/07/16
20160096823 

Aminopyridyloxypyrazole compounds


The present invention relates to novel aminopyridyloxypyrazole compounds that inhibit the activity of transforming growth factor beta receptor 1 (tgfβr1), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, preferably colon cancer, melanoma, hepatocellular carcinoma, renal cancer, glioblastoma, pancreatic cancer, myelodysplastic syndrome, lung cancer, and gastric cancer, and/or fibrosis, preferably liver fibrosis and chronic kidney disease.. .
Eli Lilly And Company


03/31/16
20160094965 

Access to wireless emergency alert information via the spectrum access system


The spectrum access system (sas) may be utilized wireless emergency alert (wea) information. The sas may be utilized to retrieve additional wea information, beyond that which was provided in a wea message.
At&t Intellectual Property I, L.p.


03/31/16
20160092723 

Elapsed-time determination apparatus, deciding apparatus, deciding method, and non-transitory computer-readable recording medium storing control program


An elapsed-time determination apparatus includes: a storage unit that stores correlation information indicating a correlation between a state of a melanophore of a fish and an amount of time elapsed since the death of the fish; an acquisition unit that acquires an image of a fish; an analysis unit that detects a state of a melanophore of a fish by analyzing an image acquired by the acquisition unit; and a determination unit that determines the amount of time elapsed since the death of the fish in accordance with the state of the melanophore of the fish detected by the analysis unit, based on the correlation information, and outputs determination results.. .
Panasonic Corporation


03/31/16
20160089319 

Actives for stimulating differentiation of keratinocytes to lighten hyperpigmented skin


A method is provided for identifying a material having an efficacy for reducing color contrast between a hyperpigmented skin lesion and skin surrounding the hyperpigmented skin lesion without directly affecting melanocytes or melanogenesis. The method includes the steps of applying a composition containing a material to be tested to the hyperpigmented skin lesion; and after an interval of time, observing whether the composition has effected at least one of inhibiting proliferation of keratinocytes, stimulating differentiation of keratinocytes, and improving compressive deformation of dermal papillae, in a basal layer of epidermis in the hyperpigmented lesion of skin..
Elc Management Llc


03/24/16
20160083379 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals, Inc.


03/24/16
20160083322 

Series of skin-whitening (lightening) compounds


The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin..
Unigen, Inc.


03/24/16
20160082024 

Use of pentacyclic triterpenoid saponin compound from szechuan melandium root for preparing hypoglycemic drug


The application of pentacyclic triterpenoid saponins, extracted from the plant of silene viscidula, is used to manufacture anti-diabetic medicaments. Having screened and researched the plants and the compounds massively, the compounds of pentacyclic triterpenoid saponins extracted and purified from silene viscidula (hereinafter called wacao saponnins), have strong effects on hyperglycemia, especially for the compounds that have mother nuclei of sinocrassulosides, which can be used to manufacture anti-diabetic medicaments..

03/17/16
20160077082 

Compositions and methods for inhibiting hmgb1 activation of melanocytes


A method of identifying a test agent as a skin tone agent. The method includes determining the level of high-mobility group protein b1 (hmgb1), messenger rna associated with the expression and/or regulation of hmgb1 (hmgb1 mrna), and/or micro-rna associated with the expression and/or regulation of hmgb1 (hmgb1 mirna) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in hmgb1 level, a downregulation in transcription of hmgb1 mrna, and/or an upregulation of hmgb1 mirna.
The Procter & Gamble Company


03/17/16
20160077080 

Method of making a skin care composition


A method of making a skin composition that includes an effective amount of skin care agent selected to inhibit hmgb1 stimulation of human melanocytes. The method includes determining the level of high-mobility group protein b1 (hmgb1), messenger rna associated with the expression and/or regulation of hmgb1 (hmgb1 mrna), and/or micro-rna associated with the expression and/or regulation of hmgb1 (hmgb1 mirna) present in the test sample, and identifying the test agent as a skin tone agent when there is no increase in hmgb1 level, a downregulation in transcription of hmgb1 mrna, and/or an upregulation of hmgb1 mirna.
The Procter & Gamble Company


03/17/16
20160074499 

Anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing culture medium of adsc-t cells in which t-antigen is introduced into adipose-derived stem cell as active ingredient


The present invention relates to an anti-inflammatory, skin-regenerative, whitening, antioxidant, or wound-healing composition containing a culture medium of adipose-derived stem cell-t (adsc-t) cells as an active ingredient, in which t-antigen is introduced into an adipose-derived stem cell. The culture medium of adsc-t cells, according to the present invention, has remarkable effects for treating or inhibiting inflammation by alleviating atopic dermatitis, which is an autoimmune disease, and inhibiting nf-κb activities through an increase of an iκbα expression.
Changwon National University Industry Academy Cooperation Corps


03/17/16
20160074314 

Topical skin care formulations comprising plant extracts


Disclosed is a method of treating a skin condition, the method comprising topically applying to skin in need thereof a composition comprising an effective amount of an aqueous or alcoholic extract from the leaf of quassia undulata, wherein the composition treats the skin condition by reducing cox-1, lipoxygenase, tyrosinase, tnf-α, melanogenesis, or mmp-1 activity in the skin.. .
Mary Kay Inc.


03/17/16
20160074293 

Cosmetic compositions and methods for inhibiting melanin synthesis


A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include bisabolol, undecylenoyl phenylalanine and/or hexyldecanol, and a material selected from the group consisting of ethyl palmitate, stearyl alcohol, bis(2-ethylhexyl)adipate, bis(2-ethylhexyl)maleate, 5-pentadecanol, 1-stearoyl-rac-glycerol, bis(2-ethylhexyl)sebacate, and mixtures thereof.
The Procter & Gamble Company


03/10/16
20160069880 

Proteins


The present invention relates to the identification of membrane proteins associated with b-cell non-hodgkin's lymphoma, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, hepatocellular carcinoma, lung cancer, lymphoid leukaemia (particularly acute t-cell leukaemia and chronic lymphocytic leukaemia), melanoma, neuroblastoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer and retinoblastoma which have utility as markers and for treatment of said cancers and which also form biological targets against which antibodies such as therapeutic antibodies (or other affinity reagents) or other pharmaceutical agents can be made.. .

03/10/16
20160068507 

Histone demethylase inhibitors


Provided herein are substituted pyrazolylpyridine, pyrazolylpyridazine, and pyrazolylpyrimidine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase.
Quanticel Pharmaceuticals, Inc.


03/10/16
20160067314 

Compositions and methods for inhibiting chemoresistance in cancer and improving response to therapy


Metastatic melanomas are highly resistant to radiation and chemotherapy from the earliest stages, which is a major factor in poor clinical outcomes. Activated leukocyte adhesion molecule (alcam)/cd166 was the gene that showed the highest correlation with detachment-induced chemoresistance.
University Of Virginia Patent Foundation


03/10/16
20160067240 

Novel allosteric inhibitors of thymidylate synthase


The current invention is directed to a class of compounds that inhibit the function of thymidylate synthase. Thymidylate synthase inhibition was noted to result in inhibition of tumor cell grow and killing of tumor cells.
University Of Florida Research Foundation, Inc.


03/10/16
20160067211 

Pharmaceutical composition


The present invention relates to a pharmaceutical composition for the prophylaxis and/or treatment of a melanoma and a precursor thereof as well as a skin and mucosa metastasis and uses and methods associated therewith.. .
Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet


03/03/16
20160063575 

Content acquisition and conversion system


The technologies presented herein relate to a centralized system for generating media content in response to a job request, particularly for transmission over radio waves. A plurality of individuals can subscribe to the centralized system to review the job request, and based thereon, can provide one or more submissions for potential incorporation into media desired by the job requester.
Wavstar, Llc


03/03/16
20160060343 

Cancer treatment


The present invention relates to methods of treating cancer, such as melanoma, by administering a ctla4 antagonist to a subject with a serum c-reactive protein (crp) concentration that is less than or equal to some amount. The invention further relates to methods of treating cancer by determining the level of serum crp concentration in a subject, and then administering a ctla4 antagonist if the crp concentration is less than or equal to a certain amount.
Pfizer Inc.


03/03/16
20160060247 

Histone demethylase inhibitors


The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds.
Quanticel Pharmaceuticals, Inc.


03/03/16
20160060234 

Cysteine derivative


And salts thereof, are superior in stability, have less odor, exhibit an eumelanin production suppressive effect, and are useful as cosmetic agents.. .

03/03/16
20160058288 

Three dimensional tissue imaging system and method


Multispectral digitized images are provided by utilizing 2 or more spectral bands, providing images and information regarding a pigmented or other differentiated tissue sample at differing depths. The images are transformed to enhance morphological patterns characteristic of melanoma, such as the statistical properties of the pigment network, image texture or homogeneity, and the lesion reflectance, in order to provide information about lesion morphology at different depths.
Mela Sciences, Inc.


02/25/16
20160052979 

Family of synthetic polynucleotide-binding peptides and uses thereof


The present invention provides novel synthetic peptides (including the tzip peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-myc genes.
Eastern Virginia Medical School


02/25/16
20160052915 

Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof


The present invention relates to the rohitukine (5,7-dihydroxy-8-(3-hydroxy-1-methyl-piperidin-4-yl)-4h-chromen-4-ones) analogs of formula a and pharmaceutically acceptable salts thereof. In addition, the invention relates to pharmaceutically acceptable compositions comprising at least one such compound, and methods of using the compounds for treating or preventing various proliferative disorders such as melanoma, leukemia, breast cancer and prostate cancer etc.
Council Of Scientific And Industrial Research




Elan topics: Folic Acid, Carbon Dioxide, Antibodies, Immune Response, High Energy, Inorganic Compounds, Electrolysis, Semiconductor Material, Semiconductor, Hydrogen Production From Water, Female Sexual Dysfunction, Dysfunction, Sexual Dysfunction, Mammography, Radiograph

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Elan for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.65

4378

469296 - 0 - 103